Contemporary heart failure evidence in 2025: a joint summary of key trials from the European Journal of Heart Failure and ESC Heart Failure Journal - PubMed
4 hours ago
- #medical-research
- #cardiovascular-disease
- #heart-failure
- Heart failure (HF) remains a major global health challenge with high morbidity, mortality, and healthcare costs.
- Increasing prevalence due to population aging, improved survival post-myocardial infarction, and rising cardiometabolic disease.
- Advances in multi-parametric biomarkers, advanced imaging, and AI-based tools enable earlier diagnosis and personalized management.
- Aetiology-specific insights (e.g., hypertensive/ischaemic heart disease, cardiomyopathies, amyloidosis, pregnancy-related HF) reshape clinical pathways.
- Key developments in guideline-directed medical therapy include early intensive strategies and expanded use of SGLT2 inhibitors and MRAs.
- Persistent gaps exist between trial evidence and real-world implementation of therapies.
- Advances in decongestion, cardio-renal interactions, valve interventions, and device-based monitoring highlight evolving HF care complexity.
- Delayed diagnosis, underuse of evidence-based therapies, and organizational barriers limit clinical impact.
- Bridging the implementation gap requires earlier prevention, precision phenotyping, and integrated multidisciplinary care.